



Dkt. 0575/50659/JPW/JML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David Baltimore et al.  
Serial No. : 08/813,323 Examiner: Y. Eyler  
Filed : March 10, 1997 Art Unit: 1642  
For : TRUNCATED CRAFT INHIBITS CD40 SIGNALING

1185 Avenue of the Americas  
New York, New York 10036

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

DECLARATION UNDER 37 C.F.R. §1.132

I, Seth Lederman, declare as follows:

1. I am an Associate Professor Medicine <sup>and director</sup> of the Laboratory of Molecular Immunology at the College of Physicians and Surgeons of Columbia University, New York, New York.
2. I am a coinventor named on the above-identified patent application.
3. The invention claimed in the above-identified patent application, namely, a protein consisting of an amino acid sequence shown in Figure 1 (SEQ ID NO: 1) truncated at the amino terminus by 323 amino acid residues up to 414 amino acid residues, or a variant thereof wherein the variant comprises a conservative amino acid substitution capable of inhibiting CD40 mediated cell activation was conceived by David Baltimore, Genhong Cheng, Aileen Cleary, Zheng-sheng Ye and me.

David Baltimore, et al.  
Serial No.: 08/813,323  
Filed: March 10, 1997  
Page 2

4. The other coauthor of Cheng, et al., "Involvement of CRAF1, a Relative of TRAF, in CD40 Signaling" (Science 267(11): 494-498) who is not a named inventor on the subject application did not contribute to the conception of the claimed invention. Specifically, David I. Hong was an undergraduate student at Columbia University and was assisting in sequencing and isolating genomic clones under my direction and supervision.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of United States Code and that false statements may jeopardize the validity of the application or any patent issuing thereon.

Seth Lederman  
Seth Lederman, M.D.

12/6/99  
Date